Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists by Gulen Hatemi et al.
RESEARCH ARTICLE Open Access
Quantiferon-TB Gold in tube assay for the
screening of tuberculosis before and during
treatment with tumor necrosis factor alpha
antagonists
Gulen Hatemi1, Melike Melikoglu1*, Fatma Ozbakir2, Koray Tascilar1 and Hasan Yazici1
Abstract
Introduction: The usefulness of interferon-gamma (IFN-g) release assays for tuberculosis screening before tumor
necrosis factor-alpha (TNF-a) antagonists and for monitoring during treatment is a contraversial issue. The aims of
this study were to determine whether TNF-a antagonists affect the results of the Quantiferon-TB Gold in-tube
assay (QTF); to assess how QTF performs in comparison with the tuberculin skin test (TST) in rheumatoid arthritis
(RA) patients who are about to start treatment with TNF-a antagonists, RA patients who are not candidates for
treatment with TNF-a antagonists, rheumatology patients with confirmed current or past tuberculosis infection,
and healthy controls, and to determine the specificity of the QTF test to differentiate leprosy patients, another
group of patients infected with mycobacteria.
Methods: The 38 RA patients who were prescribed TNF-a antagonists, 40 RA patients who were not considered
for TNF-a antagonist use, 30 rheumatology patients with a history or new diagnosis of tuberculosis, 23 leprosy
patients, and 41 healthy controls were studied. QTF and TST were done on the same day, and both were repeated
after a mean of 3.6 ± 0.2 months in patients who used TNF-a antagonists.
Results: Treatment with TNF-a antagonists did not cause a significant change in the QTF or TST positivity rate
(34% versus 42%; P = 0.64; and 24% versus 37%; P = 0.22). Patients with leprosy had a trend for a higher mean
IFN-g level (7.3 ± 8.0) and QTF positivity (61%) than did the other groups; however, the difference was not
significant (P = 0.09 and P = 0.43).
Conclusions: Treatment with TNF-a antagonists does not seem to affect the QTF test to an appreciable degree.
The higher IFN-g levels in leprosy patients deserves further attention.
Introduction
Tuberculosis infection, usually as a reactivation of latent
tuberculosis, is an important complication of treatment
with tumor necrosis factor-alpha (TNF-a)-blocking
drugs [1]. Guidelines have been developed in many
countries for screening for latent tuberculosis before
starting TNF-a antagonists [2-7]. Despite minor differ-
ences, they all include a good clinical history, physical
examination, chest radiograph, and the tuberculin skin
test (TST) [8].
Interpretation of the TST may be challenging for sev-
eral reasons, such as false-positive results caused by
Bacille Calmette-Guérin (BCG) vaccination and infection
with other mycobacteria and false-negative results
caused by immunosuppresssion and waning of the TST
over time. An increased frequency of negative TST
results has been reported in RA patients, especially
among those who were eligible for TNF-a-antagonist
use, probably related to disease severity, which by itself
might be a cause of the immunosuppressed state [9].
Other problems with the TST are difficulties in
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standardization of the administration and the reading of
the test.
The interferon gamma (IFN-g) release assays (IGRAs)
have emerged as promising alternatives to TST for
screening latent tuberculosis. The two types of commer-
cially available IGRAs are the Quantiferon test, which
measures antigen-spesific IFN-g released by circulating
T cells in whole blood, and ELISPOT, which measures
the presensitized T cells specific to Mycobacterium
tuberculosis isolated from peripheral blood mononuclear
cells, which release IFN-g. The Quantiferon-TB gold test
in-tube assay (QTF) is a newer and more practical
method. The QTF test is proposed to be more sensitive
and more specific than TST because it is not affected by
BCG vaccination and infections with other mycobacteria
[10]. However, it is hard to interpret the specificity and
sensitivity of this test, as is also true for the TST,
because no gold standard exists for diagnosing latent
tuberculosis. It has been suggested by some that the
QTF test may replace TST before starting TNF-a
antagonists [11], whereas some propose that it could be
used as an adjunct to the TST [12,13]. Still others sug-
gested that it is not cost effective and reliable enough in
immunosuppressed patients [14,15].
The follow-up of patients who are being treated with
TNF-a antagonists for tuberculosis is a further and
important problem. The duration of treatment with
these agents is usually long, and many of the patients
receive TNF-a antagonists for years. Apart from activa-
tion of latent tuberculosis, new tuberculosis infections
can also become a problem, especially in countries with
a high prevalence of tuberculosis. Guidelines are not
clear on how to monitor these patients regarding the
development of tuberculosis [2-4]. Thus it is important
to know how these tests perform in patients receiving
TNF-a antagonists.
We previously showed that the TST is not affected by
treatment with TNF-a antagonists [9]. However, we did
not know whether this was also true for the QTF test. A
former impression suggested that the IFN-g response
may be reduced in patients who are taking TNF-a
antagonists, and caution was recommended when inter-
preting negative IGRA results in such patients [16].
The specificity of the QTF test for differentiating M.
tuberculosis from other mycobacteria is another issue
that needs further attention. Leprosy is another myco-
bacterial infection that was endemic until recently in the
country where this study was conducted, as well as in
other countries where tuberculosis is still endemic. It
was shown that the surface proteins ESAT-6 and CFP-
10 used in the QTF test are also present in M. leprae
[17]. Moreover, reactivation of leprosy was reported in
three patients who were using TNF-a antagonists
[18-20]. However, the QTF test had not been studied
among patients with leprosy.
The aims of the current study were (a) to determine
whether TNF-a antagonists affect the QTF test; (b) to
determine how the QTF test performs in comparison to
the TST in rheumatoid arthritis (RA) patients treated
with TNF-a antagonists, RA patients who are not trea-
ted with TNF-a antagonists, rheumatology patients who
had had proven tuberculosis, and healthy controls; and
(c) to assess the QTF test in leprosy patients, another
group of patients infected with mycobacteria.
Materials and methods
Thirty-eight RA patients who were about to start treat-
ment with TNF-a antagonists (TNF-RA): 40 RA patients
who had not used and who were not being considered
for using TNF-a antagonists (TNF-naive RA), 30
patients with various rheumatologic conditions who had
a history or a new diagnosis of culture-positive tubercu-
losis, 23 patients with leprosy, and 41 healthy controls
(HC), who were relatives or friends of patients attending
our outpatient rheumatology clinic, were studied. Apart
from the rheumatology patients who had had tuberculo-
sis, none of the study subjects had a personal history or
a history of contact with tuberculosis. Arms of all study
subjects were checked for the presence or absence of
Bacille Calmette-Guérin (BCG) scars.
Among the TNF-RA patients, 32 (84%) of 38 were
using methotrexate, six (16%) of 38 were using sulfasala-
zine, eight (21%) of 38 were using hydroxychloroquine,
12 (32%) of 38 were using leflunomide, and 35 (92%) of
38 were using prednisolone during the first TST and
QTF tests. Among TNF-naive RA patients, 31 (78%) of
40 were using methotrexate, seven (18%) of 40 were
using sulfasalazine, six (15%) of 40 were using hydroxy-
chloroquine, eight (20%) of 40 were using leflunomide,
and 33 (83%) of 40 were using prednisolone during the
TST and QTF tests. No significant differences were
found regarding baseline treatment modalities between
the two groups. The TNF-a antagonists that were used
were etanercept in 16 patients (13.6 ± 0.6 weeks; range,
12 to 14), infliximab in 11 patients (three infusions at
weeks 0, 2, and 6), and adalimumab in 11 patients (13.5
± 0.7 weeks; range, 12 to 14).
After informed consent was obtained, blood was col-
lected for the QTF assay, and TST was administered
afterward. Quantiferon-TB Gold in-tube (Cellestis Ltd,
Victoria, Australia) was used for the QTF assay. One
milliliter of blood was drawn for each of the three test
tubes. One of these tubes contained three antigens spe-
cific for M. tuberculosis (ESAT-6, CFP-10, and TB-7.7).
The second tube was the positive control tube and was
coated with the T-cell mitogen phytohemagglutinin. The
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third tube was the negative control tube and was coated
only with EDTA. The tubes were shaken vigorously and
incubated at 37°C for 24 hours. Then the tubes were
centrifuged, and the supernatant was stored at -20°C
until the IFN-g was measured in an enzyme-linked
immunosorbent assay (ELISA) reader. The QTF test was
interpreted according to instructions of the manufac-
turer, by subtracting the amount of IFN-g in the nega-
tive control tube from that in the M. tuberculosis-
specific antigens tube. The level of IFN-g in the negative
control tube was subtracted from that in the phytohe-
magglutinin tube for positive control. For a positive test,
all three conditions had to be met: the IFN-g level in
the negative-control well (nil) should be ≤ 8.0 IU/ml;
the IFN-g level in the well containing M. tuberculosis-
specific antigens minus the negative control should be ≥
0.35 IU/ml; and this same level should be ≥ 25% of nil.
TST was administered by using the Mantoux techni-
que. The forearm was cleaned with alcohol, and 0.5 IU
of purified protein derivative (PPD) solution was
injected intradermally. The transverse diameter of the
induration was measured 48 to 72 hours later by two
independant observers. Patients put their arms through
a curtain with holes to provide blinding of the obser-
vers. The hands were also covered to prevent the
observers from recognizing the hand deformities of RA
patients.
Patients who were prescribed TNF-a antagonists had
two QTF assays and TSTs, one before the administra-
tion of the first dose of TNF-a antagonists, and the
other when they came for their second prescription,
after a mean of 3.6 ± 0.2 months. We think that all of
our patients had reached steady-state concentrations of
TNF-a antagonists by that time, because adalimumab
reaches maximum steady-state concentration at 90 ± 48
hours, etanercept, at 62 ± 29 hours, and no further
accumulation of infliximab was observed after the load-
ing dose with infusions at weeks 0, 2, and 6 [21].
Mean TST indurations in each group were compared
by using ANOVA. The number of patients with a posi-
tive TST and a positive QTF test in each group were
compared by using the Kruskal-Wallis test. The same
comparisons were made within the group of RA patients
who were prescribed TNF-a antagonists, between
before- and after-treatment values. The concordance
between the TST and QTF tests when positive TST was
defined as an induration of ≥ 10 mm was evaluated by
using kappa statistics.
The study was approved by the ethical committee of
Istanbul University, Cerrahpasa Medical School.
Results
Demographic features and QTF and TST results of each
group are given in Table 1. Treatment with TNF-a
antagonists did not significantly affect the QTF and the
TST results. The frequency of QTF positivity was 34%
before starting TNF-a antagonists and 42% after 3.6 ±
0.2 months of treatment (P = 0.64). After treatment
with TNF-a antagonists, the QTF test results did not
change in 29 of 38 patients, converted from negative to
positive in four of 38 patients, and reverted from posi-
tive to negative in three of 38 patiens. The two indeter-
minate results found before TNF-a antagonists became
positive. The mean IFN-g level in the positive-control
well increased significantly (P < 0.001) after treatment
with TNF-a antagonists, whereas the IFN-g level in the
tuberculosis-antigen well did not change (Table 2). After
treatment with TNF-a antagonists, the TST positivity
rate changed from 24% to 37% when a positive TST was
defined as ≥ 10 mm, and from 26% to 45% when
defined as ≥ 5 mm. However, the differences were not
statistically significant (P = 0.32 and P = 0.15).
Table 1 Demographic features of patients and controls








F:M 31:7 31:7 29:11 21:9 7:16 29:12
Mean age (years) 51.7 ± 14.2 51.7 ± 14.2 52.6 ± 13.5 43.0 ± 13.4 57.1 ± 9.6 41.1 ± 12.1
BCG scar (+) 24 24 25 23 16 27
QTF
(+) 13 (34%) 16 (42%) 20 (50%) 15 (50%) 14 (61%) 19 (47%)
(-) 23 (61%) 22 (58%) 19 (47%) 13 (43%) 8 (35%) 22 (53%)
Indeterminate 2 (5%) 0 1 (3%) 2 (7%) 1 (4%) 0
TST
10 mm (+) 9 (24%) 14 (37%) 22 (55%) 17 (57%) 13 (57%) 28 (68%)
5 mm (+) 10 (26%) 17 (45%) 24 (60%) 21 (70%) 14 (61%) 33 (80%)
Results in rheumatoid arthritis patients before (RA-TNF1) and after (RA-TNF2) treatment with TNF-a antagonists, rheumatoid arthritis patients who were not
prescribed TNF-a antagonists (TNF-naive RA), rheumatology patients who had current or past confirmed tuberculosis infection (TB), leprosy patients, and healthy
controls.
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The frequency of QTF positivity was lowest among
TNF-RA patients before starting TNF-a antagonists
(34%); however, the results were not significantly differ-
ent. The frequency of TST positivity was significantly
lower among TNF-RA patients before starting TNF-a
antagonists (24%) compared with the rest of the groups
(P = 0.01). The QTF positivity rate was 47% in healthy
controls, whereas the TST positivity rate was 68%.
The IFN-g levels that formed the basis for interpreting
the results of the QTF test are given in Table 2. The
RA-TNF1 group had the lowest positive control IFN-g
level (F5df = 7.58; P < 0.001) followed by the TNF-naive
RA group (F4df = 5.15; P = 0.001).
Patients with leprosy had a higher mean IFN-g level in
the tuberculosis antigen well (7.3 ± 8.0 IU/ml) and
higher QTF positivity rate (61%) than the other groups,
but the difference was not significant (P = 0.09 and P =
0.43). Their TST positivity rate was not higher than that
of the other groups (57%).
Among rheumatology patients who had had tubercu-
losis, only two had active, nontreated tuberculosis
when blood was collected for the QTF test. The QTF
test was positive in one of these patients and indeter-
minate in the other. Overall, the QTF and TST results
of the rheumatology patients who had tuberculosis in
the past were similar to those of the TNF-naive RA
patients (50% versus 50% for QTF and 55% versus 57%
for TST).
A high discordance rate was found between the QTF
test and the TST (Table 3). Among the total 204 valid
assays of QTF and TST, 59 (29%) were discordant,
when TST positivity was defined as an induration of ≥
10 mm (kappa = 0.41). We looked at the frequency of
BCG vaccination among TST(+) QTF(-) patients to see
whether this could explain the discordance in these
patients. However, the number of patients with BCG
scars among this group was not different from that of
the rest of the patients (23 (74%) of 31, versus 119
(68%) of 173; P = 0.54). We had the impression that
QTF(+) TST(-) patients had lower IFN-g levels, suggest-
ing that the low cut-off value for positivity might explain
the discordance in these patients, but 10 of 28 patients
who were QTF positive and TST negative had IFN-g
levels below 0.85 IU/ml.
Interobserver reliability for reading the TST was good
(kappa = 0.95). The interobserver reliability of the same
two observers was similar in our previous study evaluat-
ing TST in patients who were using infliximab (kappa =
0.92) [9].
Discussion
This study suggested that treatment with TNF-a
antagonists does not affect the QTF test. The QTF test
was positive in 34% of the patients before treatment and
in 42%, 3.6 months later. It was previously shown that
IFN-g production in response to phytohemagglutinin is
impaired in RA patients and is more pronounced in RA
patients with high inflammatory activity compared with
those with low activity [22,23]. The fact that the IFN-g
level in the positive-control well increased significantly
after treatment with TNF-a antagonists, probably
because of an improvement in the immunocompromised
state of these patients, whereas the IFN-g level in the
tuberculosis-antigen well did not change, also supports
the notion that results of the QTF test are not affected
by treatment with TNF-a antagonists. This is important
for showing the utility of this test during treatment with
TNF-a antagonists.
Several mechanisms are thought to play roles in the
impairment of immunity against tuberculosis in patients
Table 2 IFN-g levels in the tuberculosis antigen-stimulated wells and mitogen-stimulated wells that were used as
positive controls






Healthy controls (n = 41)
IFN-g level in tuberulosis
antigen well (IU/ml)
3.6 ± 8.4 3.0 ± 6.2 2.8 ± 5 2.3 ± 4.2 7.3 ± 8.0 3.5 ± 6.4
IFN-g level in positive
control well (IU/ml)
7.0 ± 6.4 16.1 ± 14.2a 8.7 ± 6.1 11.6 ± 12.1 12.2 ± 6.1 17.3 ± 6.4
aThe mitogen-nil level increased significantly (P < 0.001) after treatment with TNF-a antagonists.
Table 3 Discordance of QTF and TST results in each group, excluding patients with indeterminate QTF results






Healthy controls (n = 41) Total
(n = 204)
QTF (+) TST (+) 5 (13%) 9 (24%) 15 (38%) 12 (40%) 12 (52%) 16 (39%) 69 (34%)
TST (-) 8 (21%) 7 (18%) 5 (13%) 3 (10%) 2 (9%) 3 (7%) 28 (14%)
QTF (-) TST (+) 4 (11%) 5 (13%) 6 (15%) 3 (10%) 1 (4%) 12 (29%) 31 (15%)
TST (-) 19 (50%) 17 (45%) 13 (33%) 10 (33%) 7 (30%) 10 (24%) 76 (36%)
Tuberculin skin test (TST) positivity is defined as an induration of ≥ 10 mm.
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using TNF-a antagonists [24]. One explanation would
be that these drugs interfere with the secretion of IFN-g
by memory T cells [24]. This raises concern that IGRAs
may not be useful in patients who are already using
TNF-a antagonists. An ex vivo study of patients treated
with TNF-a antagonists showed that the number of
IFN-g-releasing lymphocytes and immediate release of
IFN-g after challenging with mycobacterial antigens was
significantly decreased after 14 weeks of treatment with
these drugs, compared with the initial values [25]. The
authors concluded that ELISPOT assays are not reliable
to diagnose previous or latent tuberculosis in patients
using TNF-a antagonists. However, and in line with
what we observed here, a clinical study with serial ELI-
SPOT testing before and after treatment with infliximab
suggested that ELISPOT is a reliable tool for monitoring
tuberculosis in these patients [26]. Similarly, a cross-sec-
tional study that looked at the QTF-Tb Gold test in
patients who were already using TNF-a antagonists
showed that the number of patients with a positive test
was lower in the group treated with TNF-a antagonists
and suggested that QTF-Tb Gold positivity decreased
with TNF-a antagonist use [27]. However, QTF-Tb
Gold assays were not available before treatments with
TNF-a antagonists were started in these patients. In
contrast, our results provide evidence that the QTF-Tb
Gold test is not affected by TNF-a antagonists. Thus it
is important to test how IGRAs perform in different
immunosuppressed patient populations with serial test-
ing before and after treatment with these agents, espe-
cially in settings with a high tuberculosis prevalence.
The lower QTF and TST positivity among RA patients
who are prescribed TNF-a antagonists, compared with
those who are not, is probably related to the higher dis-
ease activity in the first group. The demographic fea-
tures and the drugs used when the first QTF test was
performed were similar between the two groups. How-
ever, the first group had a higher disease activity, caus-
ing them to be prescribed TNF-a antagonists. A formal
analysis of disease activity was not performed for the
purposes of this study, but a minimum DAS28 score of
5.1 is required for prescribing TNF-a antagonists in
Turkey.
Our study showed that the positivity rate of QTF was
higher than the TST among RA patients and lower than
the TST in healthy controls. However, because no gold
standard exists for diagnosing latent tuberculosis, it is
impossible to know definitely which test is more accu-
rate. The QTF test was positive in 47% of healthy con-
trols, and the TST was positive in 68%. The estimated
prevalence of latent tuberculosis, defined as TST positiv-
ity among those who did not have a BCG vaccination, is
25% in Turkey [28]. Thus, assuming that our healthy
controls reflect the genreal population in Turkey, we
can speculate that the false-positivity rate of QTF may
be lower than that of TST, but it is probably still quite
high.
Patients with leprosy had the highest QTF positivity
rate and mean IFN-g levels in tuberculosis-antigen wells
among the groups we studied, whereas their IFN-g levels
in positive-control wells and TST positivity rate were
not higher than those in the other groups. This finding
suggests that the QTF test may give false-positive results
in leprosy patients because of cross-sensitivity with M.
tuberculosis antigens. As far as we know, this is the first
study to look at the QTF test in leprosy patients. It may
be true that patients with leprosy live in worse socioeco-
nomic conditions, spend more time in hospitals and
institutions, and may be more exposed to M. tuberculo-
sis. However, none of the patients we studied had a pre-
vious personal history or history of contact with M.
tuberculosis. Thus it is possible that infection with M.
leprae might be causing positive QTF results.
The discordance rate between the QTF test and the
TST was 29% in our study. In another study from Tur-
key, which looked at the agreement between QTF and
TST results among RA and AS patients, the QTF was
positive among 35%, the TST was positive among 66%
of the patients, and the discordance rate was 39% [29].
Another study from Turkey, this time among health-
care workers, showed a discordance rate of 37% [30].
The discordance rate is usually lower in reports from
countries where tuberculosis prevalence is low, because
most patients are both QTF and TST negative [31]. In
countries where tuberculosis is endemic, discordance
rates are usually higher [32]. It is suggested that BCG
vaccination is one of the reasons for discordance when
the TST is positive and the QTF is negative. However,
in our population, this was not the case. The number of
patients with a BCG scar was similar among TST(+)
QTF(-) patients and the rest of the patients. Conversely,
14% of our patients were QTF(+) and TST(-). These
patients usually had low IFN-g levels. This suggests that
the current low cut-off value for QTF positivity, as
advised by the manufacturer, may be reponsible for
some of the QTF(+)TST(-) results, thus increasing the
sensitivity, but decreasing the specificity of the test. In
our study population, increasing the cut-off for QTF
positivity to 0.85 IU/ml would decrease the frequency of
QTF(+)TST(-) discordant results from 14% to 9%. The
problem with the cut-off value was emphasized by
another study, which showed that reproducibility is low
among patients with IFN-g levels close to the cut-off
point [33]. Among patients with inconsistent results
between two consecutive tests, maximum IFN-g
response in either test was 0.68 IU/ml, compared with
4.99 IU/ml in persistently positive patients [33]. Thus, it
is important to interpret QTF results, not just as
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negative or positive, but quantitatively, together with
IFN-g levels in the positive-control and tuberculosis-
antigen wells, especially in immunosuppressed
populations.
We had only two rheumatology patients with active
tuberculosis at the time of this study. The other patients
who had had tuberculosis in the past had received suffi-
cient antituberculosis treatment. This may be the reason
for the low QTF positivity in this group. However, QTF
positivity rates of as low as 64% have previously been
reported among patients with active tuberculosis [34].
The main limitation of our study is the same with all
QTF and, for that matter, TST studies. No gold stan-
dard exists for diagnosing latent tuberculosis. In most
studies about the sensitivity of the QTF test for latent
tuberculosis, surrogates (such as history of exposure to a
patient with tuberculosis, sequelae on chest radiograph,
or active tuberculosis) have been used [10]. Because of
this uncertainty, we did not attempt to calculate sensi-
tivities and specificities of the QTF and TST tests. We
compared the results of patient groups with healthy
controls instead.
The other limitation of our study was that it lacked
long-term follow-up. Although the prospective nature of
our study among patients using TNF-a antagonists gave
us an idea about the effect of anti-TNF treatment on
the QTF test, we do not know whether being QTF posi-
tive shows a risk for activation of latent tuberculosis in
the long term. In our limited experience, we can point
out that among the eight patients who were QTF posi-
tive and TST negative initially, and who did not use iso-
niazid, none has developed tuberculosis. It is reasonable
to postulate that these same patients would be expected
to develop activation within the first few months of
TNF-a antagonists use, had they had latent tuberculosis.
However, data on more patients are needed to comment
on the safety of not treating such patients, as well as
patients who had QTF conversion from negative to
positive during treatment with TNF-a antagonists.
When considering QTF as a means for screening
latent tuberculosis in large populations, it has advan-
tages, such as the lack of boosting and no need for
return visits, but it also has several problems. It is
expensive and requires specialized laboratories. Its posi-
tivity rate in other mycobacteria and its reproducibility
and reliability must be studied further in immunocom-
promised populations.
Previous studies comparing QTF and TST for screen-
ing latent tuberculosis before starting TNF-a antago-
nists suggested that these tests show good concordance
in populations with low tuberculosis prevalence [35]. In
such settings, the QTF test may be used either to con-
firm positive TST results or when false-negative TST
results are suspected [12].
Conclusions
In conclusion, the QTF test does not seem to be
affected by TNF-a antagonists. In terms of screening
patients for latent tuberculosis before starting TNF-a
antagonists, no convincing data favor the QTF test or
the TST. Moreover, considering feasibility and cost-
effectiveness, it is hard to recommend the routine use of
QTF test for screening latent tuberculosis before treat-
ment with TNF-a antagonists in countries with a high
prevalence of tuberculosis. The frequency of reactivation
of tuberculosis during anti-TNF therapy has significantly
decreased with routine screening before starting treat-
ment [36]. However, this decrease seems to be related
to increased clinical and radiologic awareness rather
than to the QTF or the TST. This is further supported
by the observation that, in a large series of validated
tuberculosis cases among patients using TNF-a antago-
nists, initial TST was negative in 67% of the patients
[37].
Abbreviations
BCG: Bacille Calmette-Guérin; HC: healthy control; IFN-γ: interferon gamma;
IGRA: interferon gamma release assay; QTF: Quantiferon-TB Gold in-tube
assay; RA: rheumatoid arthritis; TNF-α: tumor necrosis factor alpha; TNF-naive
RA: RA patients who had not used and who were not being considered for
using TNF-α antagonists; TNF-RA: RA patients who were about to start
treatment with TNF-α antagonists; TST: tuberculin skin test.
Acknowledgements
The authors thank the study nurse Mine Batumlu for her help in collection
and preparation of the samples and the tuberculin skin test, and Dr Ozlem
Can, for her help with the recruitment of leprosy patients.
Author details
1Istanbul University, Cerrahpasa Medical School, Department of Internal
Medicine, Division of Rheumatology, Istanbul, Turkey. 2Istanbul University,
Cerrahpasa Medical School, Central Laboratory, Istanbul, Turkey.
Authors’ contributions
GH contributed in designing the study, collected and analyzed data, and
drafted the manuscript. MM contributed in designing the study, collection of
data, and drafting of the manuscript. FB performed the laboratory analyses.
KT contributed in collection of data. HY contributed in designing the study,
analysis of data, and drafting of the manuscript. All authors read and
approved the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 16 November 2011 Revised: 12 April 2012
Accepted: 18 June 2012 Published: 18 June 2012
References
1. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD,
BIOBADASER Group: Treatment of rheumatoid arthritis with tumor
necrosis factor inhibitors may predispose to significant increase in
tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum
2003, 48:2122-2127.
2. Koike R, Takeuchi T, Eguchi K, Miyasaka N, Japan College of Rheumatology:
Update on the Japanese guidelines for the use of infliximab and
etanercept in rheumatoid arthritis. Mod Rheumatol 2007, 17:451-458.
3. Elkayam O, Balbir-Gurman A, Lidgi M, Rahav G, Weiler-Ravel D: Guidelines
of the Israeli association of rheumatology for the prevention of
Hatemi et al. Arthritis Research & Therapy 2012, 14:R147
http://arthritis-research.com/content/14/3/R147
Page 6 of 7
tuberculosis in patients treated with TNF-α blockers. Harefuah 2007,
146:235-237, 244.
4. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J,
Emery P, Keystone EC, Schiff MH, Mease P, van Riel PL, Fleischmann R,
Weisman MH, Weinblatt ME: Updated consensus statement on biological
agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis
2007, 66(Suppl 3):iii2-iii22.
5. Centers for Disease Control and Prevention (CDC): Tuberculosis associated
with blocking agents against tumor necrosis factor-alpha: California,
2002-2003. MMWR Morb Mortal Wkly Rep 2004, 53:683-686.
6. Ding T, Ledingham J, Luqmani R, Westlake S, Hyrich K, Lunt M, Kiely P,
Bukhari M, Abernethy R, Bosworth A, Ostor A, Gadsby K, McKenna F,
Finney D, Dixey J, Deighton C, Audit and Guidelines Working Group of BSR
Clinical Affairs Committee: BHPR: BSR and BHPR rheumatoid arthritis
guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) 2010,
49:2217-2219.
7. Mariette X, Salmon D: French guidelines for diagnosis and treating latent
and active tuberculosis in patients with RA treated with TNF blockers.
Ann Rheum Dis 2003, 62:791.
8. Keystone EC, Papp KA, Wobeser W: Challenges in diagnosing latent
tuberculosis infection in patients treated with tumor necrosis factor
antagonists. J Rheumatol 2011, 38:1234-1243.
9. Hatemi G, Melikoglu M, Fresko I, Masatlioglu S, Tascilar K, Yazici H:
Infliximab does not suppress the tuberculin skin test (purified protein
derivative). J Rheumatol 2007, 34:474-480.
10. Menzies D, Pai M, Comstock G: Meta-analysis: new tests for the diagnosis
of latent tuberculosis infection: areas of uncertainty and
recommendations for research. Ann Intern Med 2007, 146:340-354.
11. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M,
Alfaro J, Perich R, Sanchez-Torres A, Pastor C, Sanchez-Schwartz C,
Medina M, Gamboa R, Ugarte M: Comparison of an interferon-gamma
assay with tuberculin skin testing for detection of tuberculosis (TB)
infection in patients with rheumatoid arthritis in a TB-endemic
population. J Rheumatol 2008, 35:776-781.
12. Bocchino M, Matarese A, Bellofiore B, Giacomelli P, Santoro G, Balato N,
Castiglione F, Scarpa R, Perna F, Signoriello G, Galati D, Ponticiello A,
Sanduzzi A: Performance of two commercial blood IFN-gamma release
assays for the detection of Mycobacterium tuberculosis infection in
patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect
Dis 2008, 27:907-913.
13. Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL: Effectiveness of the
combination of a whole-blood interferon-gamma assay and the
tuberculin skin test in detecting latent tuberculosis infection in
rheumatoid arthritis patients receiving adalimumab therapy. Arthritis
Rheum 2008, 59:800-806.
14. Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL: Comparison of an in vitro
tuberculosis interferon-gamma assay with delayed-type hypersensitivity
testing for detection of latent Mycobacterium tuberculosis: a pilot study
in rheumatoid arthritis. J Rheumatol 2008, 35:770-775.
15. Kaushik VV, Ambalavanan S, Binymin K: Comment on: Use of the
QuantiFERON TB Gold test as part of a screening programme in patients
with RA under consideration for treatment with anti-TNF-alpha agents:
the Newcastle (UK) experience. Rheumatology (Oxford) 2007, 46:1863-1864.
16. Lalvani A, Millington KA: Screening for tuberculosis infection prior to
initiation of anti-TNF therapy. Autoimmun Rev 2008, 8:147-152.
17. Geluk A, van Meijgaarden KE, Franken KL, Wieles B, Arend SM, Faber WR,
Naafs B, Ottenhoff TH: Immunological crossreactivity of the
Mycobacterium leprae CFP-10 with its homologue in Mycobacterium
tuberculosis. Scand J Immunol 2004, 59:66-70.
18. Vilela Lopes R, Barros Ohashi C, Helena Cavaleiro L, de Britto Pereira Cruz R,
da Veiga RR, Fernando Ribeiro Miranda M, Toshimitsu Yoshikawa G:
Development of leprosy in a patient with ankylosing spondylitis during
the infliximab treatment: reactivation of a latent infection? Clin
Rheumatol 2009, 28:615-617.
19. Scollard DM, Joyce MP, Gillis TP: Development of leprosy and type 1
leprosy reactions after treatment with infliximab: a report of 2 cases. Clin
Infect Dis 2006, 43:e19-e22.
20. Oberstein EM, Kromo O, Tozman EC: Type I reaction of Hansen’s disease
with exposure to adalimumab: a case report. Arthritis Rheum 2008,
59:1040-1043.
21. Nestorov I: Clinical pharmacokinetics of TNF antagonists: how do they
differ? Semin Arthritis Rheum 2005, 34(Suppl 1):12-8.
22. Stolzenburg T, Binz H, Fontana A, Felder M, Wagenhaeuser FJ: Impaired
mitogen-induced interferon-gamma production in rheumatoid arthritis
and related diseases. Scand J Immunol 1988, 27:73-81.
23. Seitz M, Napierski I, Augustin R, Hunstein W, Kirchner H: Reduced
production of interferon alpha and interferon gamma in leukocyte
cultures from patients with active rheumatoid arthritis. Scand J
Rheumatol 1987, 16:257-262.
24. Harris J, Keane J: How tumor necrosis factor blockers interfere with
tuberculosis immunity. Clin Exp Immunol 2010, 161:1-9.
25. Hamdi H, Mariette X, Godot V, Weldingh K, Hamid AM, Prejean MV,
Baron G, Lemann M, Puechal X, Breban M, Berenbaum F, Delchier JC,
Flipo RM, Dautzenberg B, Salmon D, Humbert M, Emilie D, RATIO
(Recherche sur Anti-TNF et Infections Opportunistes) Study Group:
Inhibition of anti-tuberculosis T-lymphocyte function with tumour
necrosis factor antagonists. Arthritis Res Ther 2006, 8:R114.
26. Xie X, Chen JW, Li F, Tian J, Gao JS, Zhang D: A T-cell-based enzyme-
linked immunospot assay for tuberculosis screening in Chinese patients
with rheumatic diseases receiving infliximab therapy. Clin Exp Med 2011,
11:155-161.
27. Matulis G, Jüni P, Villiger PM, Gadola SD: Detection of latent tuberculosis
in immunosuppressed patients with autoimmune diseases: performance
of a Mycobacterium tuberculosis antigen-specific interferon gamma
assay. Ann Rheum Dis 2008, 67:84-90.
28. Verem Savaşi Daire Başkanliği: Türkiye’de Tüberkülozun Kontrolü İçin Başvuru
Kitabi, Ankara 2003.
29. Inanc N, Aydin SZ, Karakurt S, Atagunduz P, Yavuz S, Direskeneli H:
Agreement between Quantiferon-TB gold test and tuberculin skin test
in the identification of latent tuberculosis infection in patients with8
rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2009,
36:2675-2671.
30. Ozdemir D, Annakkaya AN, Tarhan G, Sencan I, Cesur S, Balbay O, Guclu E:
Comparison of the tuberculin skin test and the quantiferon test for
latent Mycobacterium tuberculosis infections in health care workers in
Turkey. Jpn J Infect Dis 2007, 60:102-105.
31. Nienhaus A, Schablon A, Diel R: Interferon-gamma release assay for the
diagnosis of latent TB infection: analysis of discordant results, when
compared to the tuberculin skin test. PLoS One 2008, 3:e2665.
32. Mahomed H, Hughes EJ, Hawkridge T, Minnies D, Simon E, Little F,
Hanekom WA, Geiter L, Hussey GD: Comparison of mantoux skin test with
three generations of a whole blood IFN-gamma assay for tuberculosis
infection. Int J Tuberc Lung Dis 2006, 10:310-316.
33. Hesseling AC, Mandalakas AM, Kirchner HL, Chegou NN, Marais BJ,
Stanley K, Zhu X, Black G, Beyers N, Walzl G: Highly discordant T cell
responses in individuals with recent exposure to household tuberculosis.
Thorax 2009, 64:840-846.
34. Dewan PK, Grinsdale J, Kawamura LM: Low sensitivity of a whole-blood
interferon-gamma release assay for detection of active tuberculosis. Clin
Infect Dis 2007, 44:69-73.
35. Perry S, Sanchez L, Yang S, Agarwal Z, Hurst P, Parsonnet J: Reproducibility
of QuantiFERON-TB gold in-tube assay. Clin Vaccine Immunol 2008,
15:425-432.
36. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-
Gómez E, Mola EM, Carreño L, Figueroa M, BIOBADASER Group:
Effectiveness of recommendations to prevent reactivation of latent
tuberculosis infection in patients treated with tumor necrosis factor
antagonists. Arthritis Rheum 2005, 52:1766-1772.
37. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, Bréban M,
Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, Bretagne S, Emilie D,
Lemann M, Lortholary O, Mariette X, Research Axed on Tolerance of
Biotherapies Group: Risk of tuberculosis is higher with anti-tumor
necrosis factor monoclonal antibody therapy than with soluble tumor
necrosis factor receptor therapy: the three-year prospective French
Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum
2009, 60:1884-1894.
doi:10.1186/ar3882
Cite this article as: Hatemi et al.: Quantiferon-TB Gold in tube assay for
the screening of tuberculosis before and during treatment with tumor
necrosis factor alpha antagonists. Arthritis Research & Therapy 2012 14:
R147.
Hatemi et al. Arthritis Research & Therapy 2012, 14:R147
http://arthritis-research.com/content/14/3/R147
Page 7 of 7
